You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

~ Buy the SANCUSO (granisetron) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SANCUSO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Sancuso

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00186628 ↗	Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD	Completed	National Cancer Institute (NCI)	Phase 2	2005-06-01	To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
NCT00186628 ↗	Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD	Completed	The Leukemia and Lymphoma Society	Phase 2	2005-06-01	To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
NCT00186628 ↗	Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD	Completed	Stanford University	Phase 2	2005-06-01	To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
NCT00450801 ↗	R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma	Completed	University of Miami	Phase 2	2004-04-01	RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma.
NCT00868764 ↗	An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron	Completed	Prostrakan Pharmaceuticals	Phase 1	2009-04-01	This study aims to evaluate the effect of age and BMI on the pharmacokinetics and safety of Sancuso®.
NCT00873197 ↗	PK, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and IV Granisetron	Completed	Prostrakan Pharmaceuticals	Phase 1	2009-04-01	This study has been designed to investigate the pharmacokinetic and safety profile of the co-administration of intravenous (IV) and transdermal granisetron, as well as characterise the pharmacokinetics of multiple transdermal dosing.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Sancuso

Condition Name

Chart
Table

Condition Name for Sancuso
Intervention	Trials
Chemotherapy Induced Nausea and Vomiting	3
Healthy	2
Healthy Volunteers	2
Vomiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Sancuso
Intervention	Trials
Vomiting	11
Nausea	8
Lymphoma, Mantle-Cell	2
Lymphoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Sancuso

Trials by Country

Map
Table

Trials by Country for Sancuso
Location	Trials
United States	17
United Kingdom	2
Korea, Republic of	2
Hong Kong	1
China	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Sancuso
Location	Trials
Pennsylvania	3
Texas	3
California	3
Florida	2
Washington	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Sancuso

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Sancuso
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 2	4
[disabled in preview]	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Sancuso
Clinical Trial Phase	Trials
Completed	10
Not yet recruiting	2
Withdrawn	2
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sancuso

Sponsor Name

Chart
Table

Sponsor Name for Sancuso
Sponsor	Trials
Prostrakan Pharmaceuticals	6
Kyowa Kirin Pharmaceutical Development Ltd	3
National Cancer Institute (NCI)	3
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Sancuso
Sponsor	Trials
Industry	14
Other	12
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.